NeuroSense Therapeutics
NRSN
7 hedge funds and large institutions have $1.87M invested in NeuroSense Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
516% more capital invested
Capital invested by funds: $304K → $1.87M (+$1.57M)
8.04% more ownership
Funds ownership: 1.22% → 9.26% (+8%)
13% less funds holding
Funds holding: 8 → 7 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.02M |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$41.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$129K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$35.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$21.7K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$12.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.77M | +$2.02M | +1,584,000 | New |
|
|
MIH
2
Meitav Investment House
Bene-Beraq,
Israel
| $44.8K | -$12.7K | -10,000 | -20% |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| $36.6K | +$41.6K | +32,650 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $13.4K | – | – | – |
|
5
Morgan Stanley
New York
| $1.68K | – | – | – |
|
6
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
7
Qube Research & Technologies (QRT)
London,
United Kingdom
| $60 | – | – | – |
|
|
8
Renaissance Technologies
New York
| – | -$129K | -71,100 | Closed |
|
|
WP
9
Woodline Partners
San Francisco,
California
| – | -$35.6K | -19,581 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$21.7K | -11,928 | Closed |
|
NRSN Hedge Fund Activity: Q2 2024 in Review
7 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2024, worth a combined $1.87M — up 516% from $304K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NRSN and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.02M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $129K sold.
- 7 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2024, down from 8 in Q1 2024.
- Funds reported $1.87M of NeuroSense Therapeutics stock for Q2 2024, up 516% quarter-over-quarter.
- 2 funds opened new NeuroSense Therapeutics positions in Q2 2024 and 3 closed out, a net change of -1 holder.
- The largest NeuroSense Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $2.02M added.
- The largest NeuroSense Therapeutics seller in Q2 2024 was Renaissance Technologies, an estimated $129K sold.
Based on aggregated 13F filings for Q2 2024.